Zai Lab announces approval of TIVDAK for patients with recurrent or metastatic cervical cancer in Hong Kong

CAR-T Digest - August 2020

01 September 2025: Zai Lab announces approval of TIVDAK for patients with recurrent or metastatic cervical cancer in Hong Kong

Zai Lab announced that the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) for adult patients with recurrent or metastatic cervical cancer whose disease has progressed after chemotherapy
This marks the first antibody-drug conjugate (ADC) approved for cervical cancer in Hong Kong, offering a new treatment option where limited therapies exist
Zai Lab emphasized its ability to rapidly bring TIVDAK to patients through its established commercial infrastructure, already supporting ZEJULA in Hong Kong
TIVDAK is also under review by China’s NMPA, with the Biologics License Application accepted in March 2025, signaling potential expansion across Greater China